Oncology Medical News about sunitinib;bevacizumab;first-line treatment;metastatic renal cell carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
British Journal of Cancer, 07/02/09

Thompson Coon JS et al. - In a study to explore the evidence from all available randomised clinical trials of sunitinib and bevacizumab, in combination with interferon-α (IFN-α), in treatment of advanced metastatic renal cell carcinoma (RCC), there is evidence to suggest that treatment with sunitinib and treatment with bevacizumab plus IFN has clinically relevant and statistically significant advantages over treatment with IFN alone in pts with metastatic RCC.

Methods

Systematic literature searches were performed in 6 electronic databases.
Bibliographies of included studies were searched for further relevant studies.
Individual conference proceedings were searched using their online interfaces.
Studies were selected according to predefined criteria.
All randomised clinical trials of sunitinib or bevacizumab in combination with IFN for treating advanced metastatic RCC, in accordance with the European licensed indication, were included.
Study selection, data extraction, validation and quality assessment were performed by 2 reviewers with disagreements being settled by discussion.
Effects of sunitinib and bevacizumab (in combination with IFN-α) on progression-free survival (PFS) were compared indirectly using Bayesian Markov Chain Monte-Carlo (MCMC) sampling in Win BUGS, with IFN as a common comparator.

Results

3 studies were included.
Median PFS was significantly prolonged with both interventions (from 5 mos to between 8 and 11 mos) compared with IFN.
Overall survival was also prolonged, compared with IFN, although published data are not fully mature.
Indirect comparison suggests that sunitinib is superior to bevacizumab plus IFN in terms of PFS.

<< Previous
Targeting inhibitor of apoptosis proteins in combination with...

Next >>
Height and risk of prostate cancer in the prostate, lung,...

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09 Relevance Score: 89%

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09 Relevance Score: 88%

Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09 Relevance Score: 87%

Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09 Relevance Score: 87%

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-2a compared with sunitinib
British Journal of Cancer, 11/20/09 Relevance Score: 84%